# Clinical Trial Landscape: 03_nsclc_egfr_exon19

*Generated: 2026-01-05 18:28:37*

## Summary

- **Total Trials**: 60
- **Flagged for Review**: 0
- **Search Terms Used**: 5

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1/Phase 2 | 16 | █████ 26.7% |
| Phase 2 | 14 | ████ 23.3% |
| Phase 1 | 10 | ███ 16.7% |
| Unknown | 9 | ███ 15.0% |
| Phase 3 | 5 | █ 8.3% |
| Phase 2/Phase 3 | 4 | █ 6.7% |
| Not Applicable | 2 |  3.3% |

## Status Distribution

- **Recruiting**: 58 (96.7%)
- **Not yet recruiting**: 2 (3.3%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 3 |
| Bristol-Myers Squibb | 3 |
| Vanderbilt-Ingram Cancer Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| SWOG Cancer Research Network | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Janssen Research & Development, LLC | 2 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| University of Missouri-Columbia | 1 |
| Dragonfly Therapeutics | 1 |
| Vivace Therapeutics, Inc | 1 |
| Lung Cancer Mutation Consortium | 1 |
| AstraZeneca | 1 |
| J Ints Bio | 1 |
| Wake Forest University Health Sciences | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Carboplatin | 13 |
| Pemetrexed | 11 |
| Pembrolizumab | 10 |
| Paclitaxel | 7 |
| Biospecimen Collection | 6 |
| Cisplatin | 6 |
| Computed Tomography | 5 |
| Magnetic Resonance Imaging | 4 |
| Etoposide | 3 |
| Osimertinib | 3 |
| Nivolumab | 3 |
| Gemcitabine | 3 |
| Cyclophosphamide | 2 |
| Bevacizumab | 2 |
| Positron Emission Tomography | 2 |
| Atezolizumab | 2 |
| Amivantamab | 2 |
| Lazertinib | 2 |
| Nab-paclitaxel | 2 |
| Ipilimumab | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 60 |
| Spain | 17 |
| South Korea | 14 |
| Canada | 12 |
| Italy | 12 |
| Australia | 12 |
| France | 12 |
| United Kingdom | 11 |
| Belgium | 9 |
| China | 9 |
| Hungary | 8 |
| Poland | 8 |
| Turkey (Türkiye) | 8 |
| Japan | 8 |
| Israel | 7 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| EGFR exon 19 deletion | manual | 1.0 |
| NSCLC | manual | 1.0 |
| EGFR exon 19 deletion NSCLC | manual | 1.0 |
| EGFR exon 19 deletion non-small cell lung cancer | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07216404](https://clinicaltrials.gov/study/NCT07216404) | Phase 2 | Not yet recruiting | Alan Davis | Exploring the Safety, Acceptability... |
| [NCT07063745](https://clinicaltrials.gov/study/NCT07063745) | Phase 2/Phase 3 | Recruiting | Bristol-Myers Squibb | A Randomized Phase 2/3 Study of BMS... |
| [NCT06945484](https://clinicaltrials.gov/study/NCT06945484) | Not Applicable | Not yet recruiting | University of Utah | PILOT for The Precision Exercise Re... |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Open-Label, Multicent... |
| [NCT07223424](https://clinicaltrials.gov/study/NCT07223424) | Phase 2 | Recruiting | Diwakar Davar | Patient Preference for Subcutaneous... |
| [NCT07220096](https://clinicaltrials.gov/study/NCT07220096) | N/A | Recruiting | M.D. Anderson Cancer... | Registry Trial and Needs Assessment... |
| [NCT07090499](https://clinicaltrials.gov/study/NCT07090499) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-label Study to Inves... |
| [NCT06907615](https://clinicaltrials.gov/study/NCT06907615) | Phase 2 | Recruiting | Shanghai Henlius Bio... | An Open-label, Multi-center, Global... |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Phase 1/Phase 2 | Recruiting | Arvinas Inc. | A Phase 1/2 Clinical Trial to Evalu... |
| [NCT06975293](https://clinicaltrials.gov/study/NCT06975293) | Phase 1/Phase 2 | Recruiting | STORM Therapeutics L... | Open-label, Non-randomized, Multi-c... |
| [NCT06788912](https://clinicaltrials.gov/study/NCT06788912) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | KEYMAKER-U01 Substudy 01E: A Phase ... |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06706076](https://clinicaltrials.gov/study/NCT06706076) | Phase 1/Phase 2 | Recruiting | BlossomHill Therapeu... | A Phase 1/2 Open-Label, Multicenter... |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | Phase 2/Phase 3 | Recruiting | BioNTech SE | A Phase II/III, Multisite, Randomiz... |
| [NCT06659458](https://clinicaltrials.gov/study/NCT06659458) | N/A | Recruiting | Our Lady of the Lake... | Utilizing Long-read Sequencing to I... |
| [NCT06667076](https://clinicaltrials.gov/study/NCT06667076) | Phase 2 | Recruiting | Janssen Research & D... | A Phase 2b, Open-Label, Two-cohort ... |
| [NCT06660407](https://clinicaltrials.gov/study/NCT06660407) | Phase 2 | Recruiting | Mayo Clinic | Grid Radiotherapy for Advanced Non-... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Phase 1/Phase 2 | Recruiting | Daiichi Sankyo | A Multicenter, Randomized, Open-Lab... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06452277](https://clinicaltrials.gov/study/NCT06452277) | Phase 3 | Recruiting | Bayer | A Phase 3 Open-label, Randomized, A... |
| [NCT06162572](https://clinicaltrials.gov/study/NCT06162572) | Phase 1/Phase 2 | Recruiting | Servier Bio-Innovati... | A Phase 1b/2, Multicenter, Open-lab... |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Not Applicable | Recruiting | University of Pittsb... | Cancer Nutrition Study: CaNS - A Pi... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06262321](https://clinicaltrials.gov/study/NCT06262321) | Phase 2 | Recruiting | University of Roches... | Phase II Trial of Thoracic Radiothe... |
| [NCT06150664](https://clinicaltrials.gov/study/NCT06150664) | Phase 1 | Recruiting | Compass Therapeutics | A Phase 1, Open-Label, Multiple-Asc... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06246110](https://clinicaltrials.gov/study/NCT06246110) | Phase 2 | Recruiting | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combi... |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Phase 3 | Recruiting | Eli Lilly and Compan... | SUNRAY-01, A Global Pivotal Study i... |
| [NCT06131840](https://clinicaltrials.gov/study/NCT06131840) | Phase 1 | Recruiting | Seagen, a wholly own... | An Open-label Phase 1 Study to Inve... |
| [NCT05799274](https://clinicaltrials.gov/study/NCT05799274) | Phase 1 | Recruiting | Radiopharm Theranost... | Characterizing the Radiochemical an... |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Phase 2 | Recruiting | Hackensack Meridian ... | A Multicenter Phase II Randomized T... |
| [NCT05394831](https://clinicaltrials.gov/study/NCT05394831) | Phase 1/Phase 2 | Recruiting | J Ints Bio | A Phase 1/2, Open-label, Multi-cent... |
| [NCT05985655](https://clinicaltrials.gov/study/NCT05985655) | Phase 1/Phase 2 | Recruiting | Exscientia AI Ltd., ... | A Phase 1/2 Open-label Multicenter ... |
| [NCT05671510](https://clinicaltrials.gov/study/NCT05671510) | Phase 3 | Recruiting | OncoC4, Inc. | Phase 3, Two-stage, Randomized Stud... |
| [NCT05866302](https://clinicaltrials.gov/study/NCT05866302) | N/A | Recruiting | University of Michig... | Parametric Response Mapping (PRM) f... |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Phase 1/Phase 2 | Recruiting | Xilio Development, I... | A First-in-Human, Multicenter, Phas... |
| [NCT05501665](https://clinicaltrials.gov/study/NCT05501665) | Phase 1/Phase 2 | Recruiting | Vanderbilt-Ingram Ca... | SiCARIO (Split Course Adaptive Radi... |
| [NCT05785741](https://clinicaltrials.gov/study/NCT05785741) | Phase 1/Phase 2 | Recruiting | DualityBio Inc. | A Phase 1/2a, Multicenter, Open-Lab... |
| [NCT05800587](https://clinicaltrials.gov/study/NCT05800587) | Phase 2 | Recruiting | Fox Chase Cancer Cen... | Phase II Study of Dose Attenuated C... |
| [NCT05415358](https://clinicaltrials.gov/study/NCT05415358) | N/A | Recruiting | Wake Forest Universi... | A Prospective Study Of Immune Signa... |
| [NCT05519293](https://clinicaltrials.gov/study/NCT05519293) | Phase 1/Phase 2 | Recruiting | RedCloud Bio | A Phase I/IIa, Open-label, Dose-esc... |
| [NCT05498428](https://clinicaltrials.gov/study/NCT05498428) | Phase 2 | Recruiting | Janssen Research & D... | A Phase 2, Open-Label, Parallel Coh... |
| [NCT05736029](https://clinicaltrials.gov/study/NCT05736029) | N/A | Recruiting | OncoHost Ltd. | PROPHETIC Extended - Predicting Res... |
| [NCT05443126](https://clinicaltrials.gov/study/NCT05443126) | Phase 1/Phase 2 | Recruiting | Ellipses Pharma | A Modular, Open-label, Phase I/II S... |
| [NCT05058651](https://clinicaltrials.gov/study/NCT05058651) | Phase 2/Phase 3 | Recruiting | National Cancer Inst... | Randomized Phase II/III Trial of Fi... |
| [NCT05430009](https://clinicaltrials.gov/study/NCT05430009) | Phase 1 | Recruiting | VA Ann Arbor Healthc... | Phase I Trial of Feasibility and Sa... |
| [NCT04712877](https://clinicaltrials.gov/study/NCT04712877) | N/A | Recruiting | Lung Cancer Mutation... | LEADER Neoadjuvant Screening Trial:... |
| [NCT05061550](https://clinicaltrials.gov/study/NCT05061550) | Phase 2 | Recruiting | AstraZeneca | A Phase II, Open-label, Multicentre... |
| [NCT04665206](https://clinicaltrials.gov/study/NCT04665206) | Phase 1/Phase 2 | Recruiting | Vivace Therapeutics,... | Phase I/II, Multi-Center, Open-Labe... |

*... and 10 more trials (see trials.csv for full list)*
